0001209191-14-003013.txt : 20140113
0001209191-14-003013.hdr.sgml : 20140113
20140113214200
ACCESSION NUMBER: 0001209191-14-003013
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140109
FILED AS OF DATE: 20140113
DATE AS OF CHANGE: 20140113
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SALIX PHARMACEUTICALS LTD
CENTRAL INDEX KEY: 0001009356
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943267443
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8510 COLONNADE CENTER DRIVE
CITY: RALEIGH
STATE: NC
ZIP: 27615
BUSINESS PHONE: (919) 862-1000
MAIL ADDRESS:
STREET 1: 8510 COLONNADE CENTER DRIVE
CITY: RALEIGH
STATE: NC
ZIP: 27615
FORMER COMPANY:
FORMER CONFORMED NAME: SALIX HOLDINGS LTD
DATE OF NAME CHANGE: 19970807
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DERBYSHIRE ADAM C
CENTRAL INDEX KEY: 0001212669
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-23265
FILM NUMBER: 14525585
MAIL ADDRESS:
STREET 1: 8540 COLONNADE CENTER DRIVE
STREET 2: SUITE 501
CITY: RALEIGH
STATE: NC
ZIP: 27615
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2014-01-09
0
0001009356
SALIX PHARMACEUTICALS LTD
SLXP
0001212669
DERBYSHIRE ADAM C
8510 COLONNADE CENTER DRIVE
RALEIGH
NC
27615
0
1
0
0
EVP Finance/CFO
Common Stock
2014-01-09
4
M
0
30001
18.8733
A
209396
D
Common Stock
2014-01-09
4
S
0
2400
91.95
D
206996
D
Common Stock
2014-01-09
4
S
0
27601
91.44
D
179395
D
Option to Buy Common Stock
18.8733
2014-01-09
4
M
0
30001
0.00
D
2014-06-17
Common Stock
30001
0
D
Option to Buy Common Stock
17.63
2015-06-09
Common Stock
20000
20000
D
The exercise and sale were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2013.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.91 to $92.03, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.91 to $91.90, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
Options are 100% vested.
The reporting person's prior Forms 4 mistakenly indicated the total number of derivative securities beneficially owned was 30,000 when in fact the total number of derivative securities beneficially owned is 30,001. The reporting person's transactions and derivative security holdings reported herein reflect the correct information as of the date hereof.
/s/ Donald R. Reynolds, by Power of Attorney
2014-01-13